TAP and IMS for HIPEC
Effects of Transabdominal Plane Block and Electrical Twitch Obtaining Intramuscular Stimulation on the Postoperative Pain in Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (CRS and HIPEC): a Double-blind Randomized Control Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- GangnamSeveranceHospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-Patients who are able to do daily activity and walk independently.
Exclusion Criteria:
- Patients with history of preoperative abdominal surgery
- Patients who are unable to walk independently due to musculoskeletal disorder
- Patients who are allergic to local anesthetics
- Patients with chronic pain
- Patients with pacemaker
- Patients with endotracheal tube postoperatively
- Patients with history of substance abuse
- Pregnancy
- Patients who are unable to communicate due to mental disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: I (IVPCA)
Intravenous patient controlled analgesia will be performed.
|
Intravenous patient controlled analgesia will be performed.
|
|
Active Comparator: II (IVPCA+TAP)
Intravenous patient controlled analgesia and transversus abdominis plane block will be performed.
|
Transversus abdominis plane block will be performed.
|
|
Active Comparator: III (IVPCA, IMS, and TAP)
Intravenous patient controlled analgesia, transversus abdominis plane block, and intramuscular muscular stimulation will be performed.
|
Intramuscular electrical stimulation will be performed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain score
Time Frame: At postoperative day 1
|
Pain score will be measured using visual analogue scale (0: no pain, 10: worst imaginable pain) at postoperative day 1.
|
At postoperative day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain score
Time Frame: At postoperative day 2, 3, 5, 7, 14 and 28
|
Pain score will be measured using visual analogue scale (0: no pain, 10: worst imaginable pain) at postoperative day 0, 2, 3, 5, 7, 14 and 28.
|
At postoperative day 2, 3, 5, 7, 14 and 28
|
|
IVPCA consumption
Time Frame: At postoperative day 1, 2, and 3
|
Intravenous patient controlled analgesia consumption will be measured at postoperative day 0, 1, 2, and 3.
|
At postoperative day 1, 2, and 3
|
|
Nausea will be evaluated using 2 point scale (yes, no)
Time Frame: At postoperative day 1, 2, 3, 5 and 7
|
Nausea will be evaluated using 2 point scale (yes, no) at postoperative day 1, 2, 3, 5 and 7.
|
At postoperative day 1, 2, 3, 5 and 7
|
|
Vomiting will be evaluated using 2 point scale (yes, no)
Time Frame: at postoperative day 1, 2, 3, 5 and 7.
|
at postoperative day 1, 2, 3, 5 and 7.
|
|
|
Peak cough flow
Time Frame: At postoperative day -1, 4, 7, 14, and 28
|
Peak cough flow will be evaluated at postoperative day -1, 4, 7, 14, and 28.
|
At postoperative day -1, 4, 7, 14, and 28
|
|
Gait speed
Time Frame: day -1, 4, 7, 14, and 28
|
Gait speed will be evaluated at postoperative day -1, 4, 7, 14, and 28.
|
day -1, 4, 7, 14, and 28
|
|
Quality of life will be evaluated using QoR40 questionnaire (0-200)
Time Frame: At postoperative day 4 and 7
|
Quality of life will be evaluated using QoR40 questionnaire (0-200) at postoperative day 4 and 7.
|
At postoperative day 4 and 7
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 3-2021-0032
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.